Alzamend NeuroALZN
Market Cap: 3.04M
About: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Employees: 7
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 0
16% more capital invested
Capital invested by funds: $335K [Q4 2023] → $387K (+$52.1K) [Q1 2024]
0.38% more ownership
Funds ownership: 5.26% [Q4 2023] → 5.63% (+0.38%) [Q1 2024]
19% less funds holding
Funds holding: 16 [Q4 2023] → 13 (-3) [Q1 2024]
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for ALZN.